Kohzoh Imai
 |
Kohzoh Imai (今井浩三, Kohzoh Imai, born January 1, 1948) is a Japanese physician and oncologist specializing in molecular diagnosis and novel medical treatment of cancer. He is well known for the discovery of a melanoma-related antigen (later, it is called, Chondroitin Sulfate Proteoglycan-4 (CSPG4)) by producing a monoclonal antibody.[1] In addition, he produced monoclonal antibodies against CEA or ICAM-1 and found out they are usable in the diagnosis and the pathological analysis.[2]
He is a former professor and president of Sapporo Medical University. He was a Council Member of the Science Council of Japan (The 20th and 21st term). Also he was invited by the Emperor and Empress to their spring garden party in 2009. He was a professor and the director at Research Hospital, The Institute of Medical Science, the University of Tokyo in 2010 and is currently a project professor at the University of Tokyo and the director of Kanagawa Cancer Center Research Institute in 2014 to present. He received the Medal of Honor with Purple Ribbon in 2013.
Contribution
[edit]Imai discovered three kinds of protein tyrosine phosphatase (PTP) genes having the function of controlling the signal transduction of cancer cells.[3][4] His research on the treatment with siRNA targeting PRDM14 molecule expressed in cancer cells is soon to be clinically applied to patients in Japan.[5][6] Further, he developed the diagnostic method of a digestive tract cancer utilizing a methylation of genes expressed in cancer cells.[7]
Biography and career
[edit]Imai was born in Hakodate, Hokkaido in 1948. After receiving MD from Sapporo Medical College in 1972, he started his career at the Department of Internal Medicine (Division I) under the supervision of Professor Takeo Wada. He obtained his Ph.D. from Sapporo Medical College in 1976. He worked at The Scripps Research Institute under the supervision of Prof. RA Reisfeld and Prof S Ferrone, as a NIH post-doctoral research fellow 1978 to 1981. Upon returning to Japan, he obtained the post of lecturer at the Department of Internal Medicine (Division I) of Sapporo Medical University where he later promoted to an associate professor and to a professor in 1994. During the period, he had been to the United Kingdom to study under Professor César Milstein (Nobel Prize Laureate) at MRC Laboratory of Molecular Biology, the University of Cambridge in 1985. He was appointed to the 9th chairperson of Sapporo Medical University in 2004. Later on he was appointed to the first president of Sapporo Medical University which has been transformed from a prefectural university to a prefectural university corporation in accordance with the Local Independent Administrative Agency Act in 2007. He was appointed to a professor and the director at Research Hospital, The Institute of Medical Science, the University of Tokyo in 2010. He later appointed to the director of Center for Antibody and Vaccine Therapy, the Institute of Medical Science, the University of Tokyo in 2012. From 2014 to the present, he has been a project professor at Tokyo University, the head of Medical Innovation Promotion Office, and the director of Kanagawa Cancer Center Research Institute.
References
[edit]- ^ Imai K, Ng AK, Ferrone S (1981). "Characterization of monoclonal antibodies to human melanoma-associated antigens". J Natl Cancer Inst. 66 (3): 489–496. doi:10.1093/jnci/66.3.489. PMID 6162991.
- ^ Imai K, Moriya Y, Fujita H, Tsujisaki M, Kawaharada M, Yachi A (1984). "Immunologic characterization and molecular profile of carcinoembryonic antigen detected by monoclonal antibodies". J Immunol. 132 (6): 2992–2997. doi:10.4049/jimmunol.132.6.2992. PMID 6202769. S2CID 11282930.
- ^ Adachi M, Miyachi T, Sekiya M, Hinoda Y, Yachi A, Imai K (1994). "Structure of the human LC-PTP (HePTP) gene: similarity in genomic organization within protein-tyrosine phosphatasegenes". Oncogene. 9 (10): 3031–3035. PMID 8084610.
- ^ Adachi M, Fischer EH, Ihle H, Imai K, Jirik F, Neel B, Pawson T, Shen SH, Thomas M, Ullrich A, Zhao Z (1996). "Mammalian SH2-containing protein tyrosine phosphatase". Cell. 85 (1): 15. doi:10.1016/s0092-8674(00)81077-6. PMID 8620532. S2CID 2690057.
- ^ "乳がん細胞へカプセルで薬 東大が治験計画". 29 December 2014.
- ^ Nishikawa N, Toyota M (2007). "Gene amplification and overexpression of PRDM14 in breast cancer". Cancer Res. 67 (20): 9649–9657. doi:10.1158/0008-5472.CAN-06-4111. PMID 17942894.
- ^ Suzuki H, Watkins DN, Jair KW, Schuebel KE, Markowitz SD, Chen WD, Pretlow TP, Yang B, Akiyama Y, Engeland M, Toyota M, Tokino T, Hinoda Y, Imai K, Herman JG, Baylin SB (2004). "Epigenetic inactivation of SFRP genes allows constitutive WNT signaling in colorectal cancer". Nat Genet. 36 (4): 417–422. doi:10.1038/ng1330. PMID 15034581.
- Toyota M; Imai K; et al. (2003). "Epigenetic inactivation of CHFR in human tumors". Proc Natl Acad Sci USA. 100 (13): 7818–7823. Bibcode:2003PNAS..100.7818T. doi:10.1073/pnas.1337066100. PMC 164671. PMID 12810945.
- Takaoka A; Imai K; et al. (2003). "Integration of interferon-α/β signalling to p53 responses in tumor suppression and antiviral defence". Nature. 424 (6948): 516–523. Bibcode:2003Natur.424..516T. doi:10.1038/nature01850. PMID 12872134.
- Suzuki H; Imai K; et al. (2004). "Epigenetic inactivation of SFRP genes allows constitutive WNT signaling in colorectal cancer". Nature Genetics. 36 (4): 417–422. doi:10.1038/ng1330. PMID 15034581.
- Imai K, Takaoka A (2006). "Comparing antibody and small-molecule therapies for cancer". Nat. Rev. Cancer. 6 (9): 714–27. doi:10.1038/nrc1913. PMID 16929325. S2CID 19170671.
- Suzuki H; Imai K; et al. (2011). "Genome-wide profiling of chromatin signatures reveals epigenetic regulation of microRNA genes in colorectal cancer". Cancer Res. 71 (17): 5646–58. doi:10.1158/0008-5472.can-11-1076. PMID 21734013.
| International | |
|---|---|
| National | |
| Academics | |
